Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.68 |
| ▸ | NPY2R | P49146 | 8/20 | 0.67 |
| ▸ | NPY4R | P50391 | 8/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.67 |
| ▸ | NPY1R | P25929 | 6/20 | 0.67 |
| ▸ | KDM1A | O60341 | 2/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.63 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | KDM5A | P29375 | 1/20 | 0.62 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629341 | 1.00 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29424820 | 1.00 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29973299 | 0.99 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30017187 | 0.92 | NPY2R (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31121841 | 0.92 | NMUR2 (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625796 | 0.91 | KDM1A (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176437 | 0.91 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176414 | 0.91 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30432104 | 0.91 | TFPI (0.69) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625797 | 0.91 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| US-20260041337-A1 | CELL THERAPY FOR PATIENTS | YANG DEMAO (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | disclosed |
| EP-3835319-B1 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2025-11-19 | — | — | EP | disclosed |
| US-12458249-B2 | Cell therapy for patients | YANG DEMAO (US) | 2025-11-04 | — | — | US | disclosed |
| US-12428475-B2 | Humanized anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2025-09-30 | — | — | US | disclosed |
| US-20250243257-A1 | BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-07-31 | — | — | US | disclosed |
| US-12351627-B2 | Anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2025-07-08 | — | — | US | disclosed |
| US-20250122309-A1 | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same | OMEROS CORP (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240400639-A1 | ENGINEERED EXTRACELLULAR RECEPTOR CONSTRUCTS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-05 | — | — | US | disclosed |
| EP-2968546-B1 | METHODS OF GENERATING BIOACTIVE PEPTIDE-BEARING ANTIBODIES AND COMPOSITIONS COMPRISING THE SAME | OMEROS CORP (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | H LUNDBECK AS (DK) | 2023-06-08 | — | — | US | disclosed |
| EP-3773628-B1 | CELL THERAPY FOR PATIENTS | YANG DEMAO (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-112980967-B | Method for colony breeding of easy-to-eat compound feed for micropterus salmoides | 中国水产科学研究院珠江水产研究所 | 2023-03-14 | — | — | CN | disclosed |
| EP-4065983-A1 | METHOD FOR MAKING A FINDING FOR THE FUNCTIONALITY OF AN ANOREXIGENIC SIGNAL PATH FOR A PATIENT | Labor Berlin- Charité Vivantes Services GmbH (DE) | 2022-10-05 | — | — | EP | disclosed |
| US-11427631-B2 | Anti-ACTH antibodies and use thereof | H. LUNDBECK A/S (DK) | 2022-08-30 | — | — | US | disclosed |
| CN-112626227-B | SNPs sites related to appetite suppression of micropterus salmoides and application thereof | 中国水产科学研究院珠江水产研究所 | 2022-08-02 | — | — | CN | disclosed |
| US-20220187324-A1 | MULTIPLEXED DIAGNOSTIC TO RECOGNIZE CONCENTRATIONS OF RELATED PROTEINS AND PEPTIDES | NORTH CAROLINA STATE UNIVERSITY | 2022-06-16 | — | — | US | disclosed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| US-11293932-B2 | Multiplexed diagnostic to recognize concentrations of related proteins and peptides | NORTH CAROLINA STATE UNIVERSITY (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351627-B2 | Anti-ACTH antibodies and use thereof | CRH, MC2R, GIPR | TFPI 4870/4885NPY2R 250/4885NPY4R 87/4885 |
| US-20230174641-A1 | ANTI-ACTH ANTIBODIES AND USE THEREOF | CRH, MC2R, GIPR | TFPI 4870/4885NPY2R 250/4885NPY4R 87/4885 |
| US-11427631-B2 | Anti-ACTH antibodies and use thereof | CRH, MC2R, GIPR | TFPI 4870/4885NPY2R 250/4885NPY4R 87/4885 |
| US-20260041337-A1 | CELL THERAPY FOR PATIENTS | IL2, CSF3R, TSHR | TFPI 449/4885NPY2R 216/4885NPY4R 613/4885 |
| US-12428475-B2 | Humanized anti-ACTH antibodies and use thereof | CRH, MC2R, CRHR1 | TFPI 4802/4885NPY2R 275/4885NPY4R 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.